WELCOME TO VENENUM Biodesign

VENENUM Biodesign is an early stage drug discovery company focused on advancing drug discovery programs at our novel targets to Development Candidates. Our approach is to bring our projects to products through partnership. Our most advanced programs are in Clostridium difficile (inhibitors of CDI) and agonists of TGR5 for T2DM. We are currently discussing research collaborations in both areas.

VENENUM Biodesign…

• was established with the mission of improving patients’ lives through the discovery of therapeutic compounds against our novel biological targets. Many of our targets involve novel protein-protein or protein-DNA interactions. Others are more conventional target classes (GPCRs, enzymes etc.). Our goal is to advance our discoveries to medicine through partnership with pharmaceutical companies.
• utilizes state-of-the-art assay development and ultra-high throughput screening (UHTS) against our proprietary 6 million compound collection, protein engineering and production, cellular reagent generation, computational and structural biology, medicinal chemistry, and in vivo models.
• is a company within the Genesis Biotechnology Group (GBG) located conveniently in Hamilton, New Jersey, and is easily accessible to other academic medical centers, biotech and pharmaceutical companies in the New York/ New Jersey/ Pennsylvania area.
• has collaborative research arrangements with several for-profit and not-for-profit groups and will consider additional collaborative relationships.